CD276 and central nervous system cancer: However, currently, only two clinical trials that assessed anti-B7-H3 antibodies, namely 8H9 and MGA271, in glioma and other B7-H3-associated cancers, have posted preliminary results that confirm their safety and efficacy [83,84].